Refine by
Respiratory Distress Articles & Analysis
28 news found
What is Newborn Snoring? Oftentimes, newborns breathe noisily when they sleep. It may be caused due to extra mucus or dryness in their tiny nasal passages. However, if you notice your newborn baby actually snoring on a regular basis, consult with a doctor. If your snoring is causing issues with your partner or his/her snoring is irritating you at night, it is important that you seek timely ...
Egan was one of five scientists that founded ONY Biotech, then ONY, Inc., in 1985 in hopes of developing a lung surfactant to treat premature infants born with respiratory distress syndrome, known as RDS. A few years later, in 1988, Dr. ...
Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). ...
This allows BioCardia to initiate its First-in-Human Phase I/II trial in adult patients recovering from Acute Respiratory Distress Syndrome (ARDS) due to COVID-19, with trial initiation expected in the third quarter of 2022. ...
Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). ...
In pre-clinical data, TSC has been observed to affect oxygen diffusion to hypoxic tissues and provide a functional benefit in animal models of GBM, acute respiratory distress syndrome/acute lung injury, hemorrhagic shock, and ischemic stroke. ...
ByCervoMed
Adverse reactions included cytokine release syndrome (75.8%), neutropenia (41.9%), thrombocytopenia (40.3%), anaemia (38.7%), fatigue (32.3%), leukopenia (27.4%), lymphopenia (16.1%), nausea (14.5%), headache (14.5%), hypophosphataemia (12.9%), and upper respiratory tract infection (11.3%) (aggregated until approval). Abecma U.S. ...
Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). ...
Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). ...
Aerogen Pharma, a developer of innovative inhaled treatments for patients in critical care, and Nuance Pharma (“Nuance”), a specialty care focused biopharma with late-stage clinical programs and existing commercial operations, today announce an exclusive agreement to join forces in Greater China to develop a superior, non-invasive approach to treatment of RDS, a life-threatening ...
ByAerogen
NEW YORK, December 17, 2021 – Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that Brooklyn has been added to the ICE Biotechnology Index (NYSE:ICEBIO) following the ...
Orixha’s proprietary Lung Conservative Liquid Ventilation technology, once validated in therapeutic hypothermia, will be developed for other Critical Care conditions such as Acute Respiratory Distress Syndrome. Finally, in third place, receiving two days’ worth of eg technology development time, was INNITIUS - a company devoted to the development of ...
Targeting the treatment of at-risk patients with moderate to severe symptoms of respiratory distress, it has provided the preclinical demonstration of its efficacy against the main variants currently circulating. ...
In a randomized control trial (RCT) published in the journal Shock, the BVA-100 test has shown to reduce ICU mortality by 66% (P=0.03) and reduce ventilator days in patients suffering predominantly from acute respiratory distress syndrome and septic shock. Additionally, the analysis showed 44% of BVA test results led to a change in treatment strategy (P=0.004) ...
Neurokinin-1 Receptor Positive (NK1R+™) Allogeneic Mesenchymal Cell Therapy (BCDA-03 and 04) BioCardia is working to secure acceptance of Investigational New Drug (IND) applications for Phase I/II trials in ischemic systolic heat failure (BCDA-03) and acute respiratory distress syndrome caused by COVID-19 (BCDA-04) in 2021. The FDA recently provided ...
” Pulthera, a Delaware Incorporated Limited Liability Corporation, was formed for the express purpose of advancing medical solutions for those suffering from respiratory conditions including both acute and chronic forms of COVID-19. ...
Grassin-Delyle et al. focused on adults undergoing invasive mechanical ventilation in the intensive care unit due to severe COVID-19 or non-COVID-19 acute respiratory distress syndrome (ARDS). They performed analyses of the volatile metabolome of the expired air of the patients using a high-resolution PTR-TOF. ...
Today, ONY Biotech announced the results of a clinical trial on its aerosolized surfactant for newborns with respiratory distress syndrome (RDS), a disorder caused by lack of surfactant that can result in collapsed lungs. ...
AVM has FDA permission to begin clinical trials using AVM0703 to treat patients with COVID-19- and influenza-mediated Acute Respiratory Distress Syndrome (ARDS). Additionally, a second approved trial with AVM0703 in Non-Hodgkin’s Lymphoma will be enrolling patients shortly. ...
AVM Biotechnology has received FDA permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza patients. ...